{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:59:31Z","timestamp":1790711971785,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"DOI":"10.1007\/s00259-026-08166-w","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T02:25:14Z","timestamp":1790562314000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Stage migration in prostate cancer: the role of PSMA-PET in identifying oligometastatic disease"],"prefix":"10.1007","author":[{"given":"Francesco","family":"Mattana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Luzzago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentino","family":"Dragonetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veeru","family":"Kasivisvanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinead","family":"Conlon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Castellucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Farolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Miszczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Techma\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawel","family":"Rajwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Zattoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Reitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Montorsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuele","family":"Frassoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Bagnardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Gandaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9785-5248","authenticated-orcid":false,"given":"Francesco","family":"Ceci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"8166_CR1","unstructured":"EAU Guidelines on Prostate Cancer. Edn. presented at the EAU Annual Congress Madrid 2025. EAU Guidelines Office, Arnhem, The Netherlands. ISBN 978-94-92671-29-5."},{"issue":"2","key":"8166_CR2","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.eururo.2023.10.012","volume":"85","author":"M Miszczyk","year":"2024","unstructured":"Miszczyk M, Rajwa P, Yanagisawa T, et al. The Efficacy and Safety of Metastasis-directed Therapy in Patients with Prostate Cancer: A Systematic Review and Meta-analysis of Prospective Studies. Eur Urol. 2024;85(2):125\u201338.","journal-title":"Eur Urol"},{"issue":"2","key":"8166_CR3","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3390\/cancers17020205","volume":"17","author":"A Matsukawa","year":"2025","unstructured":"Matsukawa A, Litterio G, Cormio A, et al. An Updated Systematic Review and Network Meta-Analysis of First-Line Triplet vs. Doublet Therapies for Metastatic Hormone-Sensitive Prostate Cancer. Cancers (Basel). 2025;17(2):205.","journal-title":"Cancers (Basel)"},{"issue":"29","key":"8166_CR4","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1200\/JCO.22.00644","volume":"40","author":"MP Deek","year":"2022","unstructured":"Deek MP, Van der Eecken K, Sutera P, et al. Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials. J Clin Oncol. 2022;40(29):3377\u201382.","journal-title":"J Clin Oncol"},{"issue":"36","key":"8166_CR5","doi-asserted-by":"publisher","first-page":"5561","DOI":"10.1200\/JCO.23.00985","volume":"41","author":"G Francolini","year":"2023","unstructured":"Francolini G, Allegra AG, Detti B, et al. Stereotactic Body Radiation Therapy and Abiraterone Acetate for Patients Affected by Oligometastatic Castrate-Resistant Prostate Cancer: A Randomized Phase II Trial (ARTO). J Clin Oncol. 2023;41(36):5561\u20138.","journal-title":"J Clin Oncol"},{"issue":"11","key":"8166_CR6","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","volume":"36","author":"CE Kyriakopoulos","year":"2018","unstructured":"Kyriakopoulos CE, Chen YH, Carducci MA, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol. 2018;36(11):1080\u20137.","journal-title":"J Clin Oncol"},{"issue":"5","key":"8166_CR7","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","volume":"20","author":"K Fizazi","year":"2019","unstructured":"Fizazi K, Tran N, Fein L, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20(5):686\u2013700.","journal-title":"Lancet Oncol"},{"issue":"10231","key":"8166_CR8","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395(10231):1208\u201316.","journal-title":"Lancet"},{"issue":"12","key":"8166_CR9","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021;385(12):1091\u2013103.","journal-title":"N Engl J Med"},{"issue":"11","key":"8166_CR10","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1001\/jama.280.11.969","volume":"280","author":"AV D\u2019Amico","year":"1998","unstructured":"D\u2019Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969\u201374.","journal-title":"JAMA"},{"issue":"2","key":"8166_CR11","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","volume":"40","author":"JI Epstein","year":"2016","unstructured":"Epstein JI, Egevad L, Amin MB, et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol. 2016;40(2):244\u201352.","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"8166_CR12","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1007\/s00259-017-3670-z","volume":"44","author":"WP Fendler","year":"2017","unstructured":"Fendler WP, Eiber M, Beheshti M, et al. 68Ga-PSMA PET\/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2017;44(6):1014\u201324.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"8166_CR13","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1007\/s00259-021-05245-y","volume":"48","author":"F Ceci","year":"2021","unstructured":"Ceci F, Oprea-Lager DE, Emmett L, et al. E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. Eur J Nucl Med Mol Imaging. 2021;48(5):1626\u201338.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"8166_CR14","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","volume":"83","author":"R Seifert","year":"2023","unstructured":"Seifert R, Emmett L, Rowe SP, et al. Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework (PROMISE V2). Eur Urol. 2023;83(5):405\u201312.","journal-title":"Eur Urol"},{"issue":"2","key":"8166_CR15","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.euo.2023.01.014","volume":"6","author":"F Mattana","year":"2023","unstructured":"Mattana F, Muraglia L, Rajwa P, et al. Metastatic Sites\u2019 Location and Impact on Patient Management After the Introduction of PSMA PET in Newly Diagnosed and Biochemically Recurrent Prostate Cancer: A Critical Review. Eur Urol Oncol. 2023;6(2):128\u201336.","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"8166_CR16","first-page":"130","volume":"37","author":"JR Garc\u00eda Garz\u00f3n","year":"2018","unstructured":"Garc\u00eda Garz\u00f3n JR, de Arcocha Torres M, Delgado-Bolton R, et al. 68Ga-PSMA PET\/CT in prostate cancer. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2018;37(2):130\u20138.","journal-title":"Rev Esp Med Nucl Imagen Mol (Engl Ed)"},{"issue":"12","key":"8166_CR17","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1007\/s00259-023-06332-y","volume":"50","author":"A Holzgreve","year":"2023","unstructured":"Holzgreve A, Unterrainer M, Calais J, et al. Is PSMA PET\/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial. Eur J Nucl Med Mol Imaging. 2023;50(12):3750\u20134.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"8166_CR18","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, Tran N, Fein L, et al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med. 2017;377(4):352\u201360.","journal-title":"N Engl J Med"},{"issue":"5","key":"8166_CR19","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.ijrobp.2022.04.048","volume":"113","author":"C Zamboglou","year":"2022","unstructured":"Zamboglou C, Strouthos I, Sahlmann J, et al. Metastasis-Free Survival and Patterns of Distant Metastatic Disease After PSMA-PET-Guided Salvage Radiation Therapy in Recurrent or Persistent Prostate Cancer After Prostatectomy. Int J Radiat Oncol Biol Phys. 2022;113(5):1015\u201324.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"8166_CR20","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","volume":"36","author":"P Ost","year":"2018","unstructured":"Ost P, Reynders D, Decaestecker K, et al. Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial (STOMP). J Clin Oncol. 2018;36(5):446\u201353.","journal-title":"J Clin Oncol"},{"issue":"11","key":"8166_CR21","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1001\/jamaoncol.2021.3771","volume":"7","author":"TA Hope","year":"2021","unstructured":"Hope TA, Eiber M, Armstrong WR, et al. Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial. JAMA Oncol. 2021;7(11):1635\u201342.","journal-title":"JAMA Oncol"},{"key":"8166_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-023-06490-z","author":"M Bauckneht","year":"2023","unstructured":"Bauckneht M, Checcucci E, Cisero E, et al. The prognostic role of next-generation imaging-driven upstaging in newly diagnosed prostate cancer patients. Eur J Nucl Med Mol Imaging. 2023. https:\/\/doi.org\/10.1007\/s00259-023-06490-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10336","key":"8166_CR23","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","volume":"399","author":"K Fizazi","year":"2022","unstructured":"Fizazi K, Foulon S, Carles J, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u00d72 factorial design. Lancet. 2022;399(10336):1695\u2013707.","journal-title":"Lancet"},{"key":"8166_CR24","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","volume":"386","author":"MR Smith","year":"2022","unstructured":"Smith MR, Hussain M, Saad F, et al. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer (ARASENS). N Engl J Med. 2022;386:1132\u201342.","journal-title":"N Engl J Med"},{"issue":"5","key":"8166_CR25","doi-asserted-by":"publisher","first-page":"675","DOI":"10.2967\/jnumed.120.246603","volume":"62","author":"A Farolfi","year":"2021","unstructured":"Farolfi A, Hirmas N, Gafita A, et al. Identification of PCWG3 Target Populations Is More Accurate and Reproducible with PSMA PET Than with Conventional Imaging: A Multicenter Retrospective Study. J Nucl Med. 2021;62(5):675\u20138.","journal-title":"J Nucl Med"},{"issue":"24","key":"8166_CR26","doi-asserted-by":"publisher","first-page":"7448","DOI":"10.1158\/1078-0432.CCR-19-1050","volume":"25","author":"WP Fendler","year":"2019","unstructured":"Fendler WP, Weber M, Iravani A, et al. Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2019;25(24):7448\u201354.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"8166_CR27","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","volume":"6","author":"R Phillips","year":"2020","unstructured":"Phillips R, Shi WY, Deek M, et al. Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial. JAMA Oncol. 2020;6(5):650\u20139.","journal-title":"JAMA Oncol"},{"issue":"9","key":"8166_CR28","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.3390\/cancers14092073","volume":"14","author":"T H\u00f6lscher","year":"2022","unstructured":"H\u00f6lscher T, Baumann M, Kotzerke J, et al. Local Control after Locally Ablative, Image-Guided Radiotherapy of Oligometastases Identified by Gallium-68-PSMA-PET in Castration-Sensitive Prostate Cancer Patients (OLI-P). Cancers (Basel). 2022;14(9):2073.","journal-title":"Cancers (Basel)"},{"issue":"9","key":"8166_CR29","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1007\/s00259-022-05741-9","volume":"49","author":"F Ceci","year":"2022","unstructured":"Ceci F, Rovera G, Iorio GC, et al. Event-free survival after 68 Ga-PSMA-11 PET\/CT in recurrent hormone-sensitive prostate cancer (HSPC) patients eligible for salvage therapy. Eur J Nucl Med Mol Imaging. 2022;49(9):3257\u201368.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"8166_CR30","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1007\/s00259-020-04809-8","volume":"47","author":"D Deandreis","year":"2020","unstructured":"Deandreis D, Guarneri A, Ceci F, et al. 68Ga-PSMA-11 PET\/CT in recurrent hormone-sensitive prostate cancer (HSPC): a prospective single-centre study in patients eligible for salvage therapy. Eur J Nucl Med Mol Imaging. 2020;47(12):2804\u201315.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8166_CR31","doi-asserted-by":"crossref","unstructured":"Zamboglou C, Strouthos I, Sahlmann J et al. Metastasis-Free Survival and Patterns of Distant Metastatic Disease After Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET)-Guided Salvage Radiation Therapy in Recurrent or Persistent Prostate Cancer After Prostatectomy. Int J Radiat Oncol Biol Phys. 2022;113(5):1015\u20131024. doi: 10.1016\/j.ijrobp.2022.04.048. Epub 2022 Jun 3. PMID: 35659629.","DOI":"10.1016\/j.ijrobp.2022.04.048"},{"issue":"3","key":"8166_CR32","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/S1470-2045(24)00730-7","volume":"26","author":"G Marvaso","year":"2025","unstructured":"Marvaso G, Corrao G, Zaffaroni M, et al. ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial. Lancet Oncol. 2025;26(3):300\u201311.","journal-title":"Lancet Oncol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08166-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08166-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08166-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:02:21Z","timestamp":1790708541000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-08166-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":32,"alternative-id":["8166"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-08166-w","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"6 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the coordinating center (IRCCS Istituto Europeo di Oncologia, Milan).","order":1,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This manuscript does not contain any individual person\u2019s data, individual details, images, or videos.","order":3,"name":"Ethics","label":"Consent to Publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare they have no financial or non-financial interests that are directly related to the work submitted for publication.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}